Item | Group 1 (heparin) | Group 2 (TauroLockā¢) | P value |
---|---|---|---|
No. of patients | 90 | 89 | - |
Male (proportion in %) | 51 (57) | 60 (67) | 0.16 |
Female (proportion in %) | 39 (43) | 29 (33) | Ā |
Age (years): median | 10.4 | 7.2 | 0.52 |
āāāIQRĪ | 5.2 to 14.7 | 3.7 to 16.1 | Ā |
āāāRange | 0.2 to 35.2 | 0.0 to 35.4 | Ā |
CVAD utilization days | Ā | Ā | Ā |
āāāCumulative No. | 6,086 | 6,705 | # |
āāāPort | 3,672 | 3,989 | Ā |
āāāBroviac | 2,414 | 2,716 | Ā |
Malignancy No. (%) | Ā | Ā | 0.09 |
āāāALL | 21 (23) | 26 (29) | Ā |
āāāAML | 3 (3) | 6 (7) | Ā |
āāāNHL and HD | 15 (17) | 7 (8) | Ā |
āāāSolid tumor | 30 (33) | 22 (25) | Ā |
āāāZNS | 18 (20) | 27 (30) | Ā |
āāāMAS | 2 (2) | 0 (0) | Ā |
āāāMDS | 0 (0) | 1 (1) | Ā |
āāāLCH | 1 (1) | 0 (0) | Ā |
Malignancy in relapse No. (%) | 16 (18) | 13 (15) | 0.69 |
No of patients with | Ā | Ā | 0.41 |
Port (proportion in %) | 68 (76) | 62 (70) | Ā |
Broviac (proportion in %) | 22 (24) | 27 (30) | Ā |
CVAD removal due to infection: No. (%) | 4 (4.4) | 3 (3.4)Ī© | 1.00 |